Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 40-49

  Deveney, A M ^a   Waddington, J L ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

"D1 like" and "D2 like"; A 68930; Atypical antipsychotics; Clozapine; Dopamine; Grooming; ICI 204,636; Olanzapine; Receptors; Vacuous chewing

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOMPERIDONE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EMONAPRIDE; N (3 HYDROXYPHENETHYL) N (PHENETHYL)PROPYLAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PIFLUTIXOL; QUETIAPINE; RADIOLIGAND;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG SELECTIVITY; GROOMING; LIGAND BINDING; LOCOMOTION; MALE; MASTICATION; MYOCLONUS; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; SNIFFING; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHROMANS; CLOZAPINE; DIBENZOTHIAZEPINES; DOPAMINE AGONISTS; MALE; PHENETHYLAMINES; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOISOMERISM;

EID: 0029916385     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245604     Document Type: Article

References (50)

1. 1 receptor. J Neurochem 47:1822-1831
2. Andersen PH, Gingrich JA, Bates MD, Dearry A, Falardeau P, Senogles SE, Caron M (1990) Dopamine receptor subtypes: beyond the D-1/D-2 classification. Trends Pharmacol Sci 11: 231-236
3. 1 receptor antagonists. Eur J Pharmacol 219:45-52
4. Arnt J, Hyttel J (1986) Inhibition of SK&F 38393- and pergolide-induced circling in rats with unilateral 6-OHDA lesion is correlated to dopamine D-1 and D-2 receptor affinities in vitro. J Neural Transm 67:225-240
5. Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324:746-754
6. Barlow RB (1983) Biodata handling with microcomputers. Elsevier, Amsterdam
7. Chipkin RE, Latranyi MB (1987) Similarity of clozapine and SCH 23390 in reserpinized rats suggest a common mechanism of action. Eur J Pharmacol 136:371-375
8. Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (1988) Pharmacological profile of SCH 39166: a dopamine D-1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102
9. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1991) Drugs acting at D-1 and D-2 receptors induce identical purposeless chewing in rats which can be differentiated by cholinergic manipulation. Psychopharmacology 103:503-512
10. Coward DM, Imperato A, Urwyler S, White TG (1989) Biochemical and behavioural properties of clozapine. Psychopharmacology 99 [Supplement]:S6-S12
11. 2 dopamine receptor-mediated behaviours. Eur J Pharmacol 159: 141-147
12. Daly SA, Waddington JL (1992) Two directions of dopamine D-1/D-2 receptor interaction in studies of behavioural regulation:a finding generic to four new, selective dopamine D-1 antagonists. Eur J Pharmacol 213:251-258
13. Daly SA, Waddington JL (1993) Behavioural evidence for "D-1-like" dopamine receptor subtypes in rat brain using the new isochroman agonist A 68930 and isoquinoline antagonist BW 737C. Psychopharmacology 113:45-50
14. 2-like" agonist, RU 24213. Br J Pharmacol 113:839-844
15. DeNinno MP, Schoenleber R, MacKenzie R, Britton DR, Asin KE, Briggs C, Trugman JM, Ackerman M, Artman L, Bednarz L, Bhatt R, Curzon P, Gomez E, Kang CH, Suttsworth J, Kebabian JW (1991) A 68930: a potent agonist selective for the dopamine D-1 receptor. Eur J Pharmacol 1991;209-219
16. Deutch AY, Moghaddam B, Innis RB (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 4:121-156
17. 1-like dopamine receptors not linked to adenylyl cyclase. Br J Pharmacol (in press)
18. 1-like" receptors that inhibits dopamine-sensitive adenylyl cyclase. Eur J Pharmacol 234:135-136
19. 2 receptors in the effects of the classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur J Pharmacol 196:103-108
20. Euvrard C, Ferland L, DiPaulo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, Bossier JR (1980) Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. Neuropharmacology 19:379-386
21. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 49:538-544
22. Heal DJ, Czudek C, Buckett WR (1994) Common profile of D1 receptor antagonists and atypical antipsychotic drugs revealed by analysis of dopamine turnover. Prog Neuropsychopharmacol Biol Psychiatry 18:803-821
23. ™ in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia. Eur Neuropsychopharmacol 4: 384-385
24. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789-796
25. 1-receptor antogonist SCH 39166 in schizophrenia. Neuropsychopharmacology 10 [Supplement 3, part 2]:32S
26. 1 antagonists evaluated in monkeys and in an open clinical study. Psychopharmacology 114:B5
27. 2+ mobilisation in Xenopus oocytes. Proc Natl Acad Sci USA 87:2196-2200
28. Mailman RB, Schulz DW, Kilts CD, Lewis MH, Rollema H, Wyrick S (1986) Multiple forms of the D-1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects. Psychopharmacol Bull 22:593-598
29. Meltzer HY (1991) The mechanism of action of novel antipsychotic drugs. Schizophr Bull 17:263-287
30. 1 values. J Pharmacol Exp Ther 251:238-246
31. Migler BM, Warawa EJ, Malick JB (1993) Seroquel:behavioural effects in conventional and novel tests for atypical antipsychotic drug. Psychopharmacology 112:299-307
32. Molloy AG, Waddington JL (1984) Dopaminergic behaviour stereospecifically promoted by the D-1 agonist R-SK&F 38393 and selectively blocked by the D-1 antagonist SCH 23390. Psychopharmacology 82:409-410
33. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioural pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
34. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
35. Murray AM, Waddington JL (1989a) Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology 98:245-250
36. Murray AM, Waddington JL (1989b) The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction. Eur J Pharmacol 160:377-384
37. 2 receptor-mediated function: behavioural indices. Eur J Pharmacol 186:79-86
38. Rosengarten H, Schweitzer JW, Friedhoff AJ (1983) Induction of oral dyskinesias in naive rats by D-1 stimulation. Life Sci 33:2479-2482
39. Rosengarten H, Schweitzer JW, Friedhoff AJ (1986) Selective dopamine D-2 receptor reduction enhances a D-1 mediated oral dyskinesia in rats. Life Sci 39:29-35
40. Sailer CF, Salama AI (1993) Seroquel:biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292
41. 4. Neuropsychopharmacology 7:261-284
42. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350:610-614
43. 5 dopamine receptor mechanisms in relation to antipsychotic activity. In: Barnes TRE (ed) Antipsychotic drugs and their side effects. Academic Press, London, pp 65-85
44. Waddington JL (1995) The clinical psychopharmacology of antipsychotic drugs in schizophrenia. In: Hirsch SR, Weinberger DR (eds) Schizophrenia, Blackwell, Oxford, pp 341-357
45. Waddington JL, Daly SA (1993) Regulation of unconditioned motor behaviour by D-1:D-2 interactions. In: Waddington JL (ed) D-1:D-2 dopamine receptor interactions: neuroscience and psychopharmacology. Academic Press, London, pp 51-78
46. Waddington JL, Daly SA, McCauley PG, O'Boyle KM (1994) Levels of functional interaction between "D-1-like" and "D-2 like" dopamine receptor systems. In: Niznik HB (ed) Dopamine receptors and transporters. Marcel Dekker, New York, pp 511-537
47. Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM (1995) Behavioural pharmacology of "D-1-like" dopamine receptors: further subtyping, new pharmacological probes and interactions with "D-2-like" receptors. Prog Neuropsychopharmacol Biol Psychiatry (in press)
48. Wadenberg ML, Ahlenius S, Svensson TH (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanism of action of clozapine. Psychopharmacology 110:273-279
49. White FJ, Hu XT (1993) Electrophysiological correlates of D-1:D-2 interactions. In: Waddington JL (ed) D-1:D-2 dopamine receptor interactions:neuroscience and psychopharmacology. Academic Press, London, pp 79-114
50. Wood AJ, Beasley CM, Tollefson GD, Tran PV (1994) Efficacy of olanzapine in the positive and negative symptoms of schizophrenia. Eur Neuropsychopharmacol 4:224-225